[Treatment and prevention of paroxysmal atrial fibrillation and flutter with quinidine retard].
The ability of quinidine retard of restoring sinus rhythm and further maintenance after successful regulation were checked in 42 patients with flutter and fibrillation in an open clinical trial. Quinidine retard restores the sinus rhythm in less patients (60.0%) than quinidine sulphate (81,8%). At the same time, it maintains sinus rhythm in 91,4 per cent of the cases in anti-recurrence treatment. That makes quinidine retard adequate for long-term administration.
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D001282:Atrial Flutter / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011802:Quinidine / Q000009:adverse effects / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D011802:Quinidine
Lechenie i profilaktika na pristŭpnoto predsŭrdno mŭzhdene i treptene s khinidin retard.